Navigation Links
Vermillion Reports Third Quarter 2013 Results
Date:11/14/2013

AUSTIN, Texas, Nov. 14, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, reported on its financial results for the third quarter ended September 30, 2013.

Q3 2013 Financial Results
Total revenue in the third quarter of 2013 was $330,000 compared to $319,000 in the same year-ago quarter. Third quarter 2013 revenue was comprised of $216,000 in OVA1® product sales and $114,000 in license revenue.

Third quarter of 2013 product revenue was derived from 4,328 OVA1 tests performed at the fixed $50 per test as reported by Quest Diagnostics. This represents a 5.6% increase in test volume compared to approximately 4,100 OVA1 tests performed in the year-ago quarter. Although covered lives have decreased to approximately 67.0 million due to the previously announced BlueCross BlueShield Technical Evaluation Center position, it did not affect test sale volumes for the quarter.

The OVA1 product revenue in both periods does not include the additional royalty component of revenue based on 33% of Quest Diagnostics gross margin. Vermillion recognizes this portion of revenue when it is reported by Quest Diagnostics in an annual 'true-up' after the end of the calendar year. The true-up is based on reimbursed and unreimbursed tests for which Quest Diagnostics considers the payment status as final.

Total operating expenses were $2.6 million in both the third quarter of 2013 and the same year-ago quarter. For the nine months ended September 30, 2013, total operating expenses were $7.9 million as compared to $9.0 million in the same year-ago period.

Net loss for the third quarter was $2.3 million or $(0.10) per share, as compared to a net loss of $2.0 million or $(0.13) per share in the same year-ago quarter. For the nine months ended September 30, 2013, net loss was $7.0 million or $(0.36) per share as compared to a net loss of $5.8 million or $(0.39
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. American Journal of Obstetrics & Gynecology Publishes New Clinical Study Showing Positive Performance of Vermillions OVA1 Test in Presurgical Detection of Early-Stage Ovarian Cancer
2. American Journal of Obstetrics & Gynecology Publishes New Clinical Study Showing Positive Performance of Vermillions Ovarian Cancer Test, OVA1
3. Vermillion Sets Third Quarter 2013 Conference Call for Thursday, November 14, 2013
4. Vermillion Appoints Dr. Eric Varma to its Board of Directors
5. Vermillion Supports First World Ovarian Cancer Day and Effort to Raise Awareness of the Need for Better Diagnosis and Treatment
6. Vermillion Sets First Quarter 2013 Conference Call for Wednesday, May 15, 2013
7. Vermillion Appoints Thomas McLain as President and Chief Executive Officer
8. Vermillion Reports Fourth Quarter and Full Year 2012 Results
9. Vermillion to Discuss Preliminary Results for Fourth Quarter and Full Year 2012 on Wednesday, February 20, 2013, at 4:30 p.m. ET
10. Gynecologic Oncology Publishes New Clinical Study Showing Positive Performance of OVA1, Vermillions Ovarian Cancer Test
11. Vermillion Appoints Bruce A. Huebner as Interim Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014  Surgical Theater, LLC announced today ... Business Advisory Board. New members include Ori ... Business Development and New Technologies for Given Imaging ... Senior Vice President and General Manager of Philips ... flight simulation technology to brain surgery and has ...
(Date:7/28/2014)... 2014  VigeneTech, Inc, in collaboration with BioLegend, ... Analysis Software, an OEM software solution for analysis ... and offers varieties of bead-based multi-analyte immunoassay products ... of VigeneTech,s data analysis software, FCS data files ... reported LEGENDplex™ software is a ...
(Date:7/28/2014)... July 28, 2014  Array BioPharma Inc. (Nasdaq: ... the fourth quarter and full year of ... to discuss those results on Tuesday, August ... and Michael Carruthers , Chief Financial ... August 12, 2014Time:9:00 a.m. Eastern TimeToll-Free:(800) 708-4540Toll:(847) ...
Breaking Medicine Technology:Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 2Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 3Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 4Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 5VigeneTech Releases New Powerful Software for Flow Cytometry Data Analysis 2
... oncology: most, actively researched disease area Researchers ... reagent performance ... Strategic Diagnostics,Inc. (Nasdaq: SDIX ) -- today announced ... reagents in support of oncology-based research and,discovery. These high-quality ...
... FASgen,s fatty acid synthase,inhibitor (FASi) compounds, led ... xenograft cell line tested, in both orthotopic,and flank ... H1975; LX7); two,ovarian; breast; and, colon. In many ... been shown in extensive preclinical studies to,be remarkably ...
Cached Medicine Technology:Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog 2Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog 3Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog 4Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog 5FASgen Announces Significant Milestone in Its Cancer Drug Development Program 2
(Date:7/28/2014)... 2014 Parker Waichman LLP, a personal injury ... that the heroes of 9/11 are never forgotten, comments that ... important deadline. According to a VCF message dated ... cancer on or before October 12, 2012 must file a ... and others who were allegedly injured by the toxic dust ...
(Date:7/28/2014)... HealthDay Reporter MONDAY, July ... relieve sleep apnea in children, but a new study confirms ... if they,re already overweight. The researchers said that,s a ... of health problems -- including, ironically, sleep apnea. But they,re ... Instead, they said, doctors and parents should be aware that ...
(Date:7/28/2014)... Sarasota-based FCCI Insurance Group (FCCI) was recently ... Still headquartered in Sarasota where it was originally founded ... the top ten of the Best Large Companies category. ... August issue of Florida Trend magazine. One-hundred companies are ... #7 for 2014, FCCI has been in the top ...
(Date:7/28/2014)... for patients with one of the UK,s most common ... Chronic obstructive pulmonary disease (COPD) is the name for ... to long-term damage to the lungs. Often linked ... of all hospital admissions in the UK, with a ... they are discharged. , A team of ...
(Date:7/28/2014)... 2014 The report “Industrial Enzymes ... & Beverages, Cleaning Agents, Bio-Fuel, Animal Feed), & ... defines and segments the global industrial enzymes market ... for industrial enzymes. It also identifies driving and ... with analysis of trends, opportunities, burning issues, winning ...
Breaking Medicine News(10 mins):Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 2Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 3Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 2Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 3Health News:FCCI Insurance Group Makes Top 100 Best Companies List – and is the Only Florida-Headquartered Company in Top Ten 2Health News:FCCI Insurance Group Makes Top 100 Best Companies List – and is the Only Florida-Headquartered Company in Top Ten 3Health News:New research to tackle treatment for lung disease 2Health News:New research to tackle treatment for lung disease 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 4
... Tenn., Nov. 2 Brookdale Senior Living Inc. (NYSE: ... for the third quarter of 2009. , Bill ... results this quarter which build on the success of the ... operating effectively in today,s difficult environment as evidenced by our ...
... FDA NOTE TO CORRESPONDENTS , SILVER SPRING, ... Administration (FDA) today released a listing of eight recent ... products. These updates can be accessed from the agency,s ... You can sign-up for e-mail notices of new ...
... Nov. 2 The Ensign Group, Inc. (Nasdaq: ENSG ... nursing, rehabilitative care services, hospice care and assisted living companies, ... year 2009. , (Logo: http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO ) , ... , Total revenue was a record $132.9 million, up ...
... Highest Levels of BPA Were Detected in Some Samples of Green ... Levels Shown to Cause Harm in Animal Studies; FDA,s Safety Standards ... 2 Consumer Reports, latest tests of canned foods, including ... of the 19 name-brand foods tested contain measurable levels of Bisphenol ...
... patients with HER2 positive tumors one centimeter or smaller are ... those with early-stage disease who do not express the aggressive ... University of Texas M. D. Anderson Cancer Center. The ... Oncology , is the first large study to analyze this ...
... who received influenza vaccine during pregnancy were hospitalized at ... according to preliminary results of an ongoing study by ... the study October 29 at the 47th annual meeting ... Influenza is a major cause of serious ...
Cached Medicine News:Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 2Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 3Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 4Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 5Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 6Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 7Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 8Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 9Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 10Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 11Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 12Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 13Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 14Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 15Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 16Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 17Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 18Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 19Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 20Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 21Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 22Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 23Health News:FDA CONSUMER HEALTH INFORMATION UPDATES: Fraudulent H1N1 flu products, hearing aids, sound amplifiers, tobacco regulation, FDA's international posts, LASIK eye surgery, and FDA MedWatch safety alerts 2Health News:FDA CONSUMER HEALTH INFORMATION UPDATES: Fraudulent H1N1 flu products, hearing aids, sound amplifiers, tobacco regulation, FDA's international posts, LASIK eye surgery, and FDA MedWatch safety alerts 3Health News:The Ensign Group Reports Third Quarter 2009 Adjusted Earnings of $0.38 per Share 2Health News:The Ensign Group Reports Third Quarter 2009 Adjusted Earnings of $0.38 per Share 3Health News:The Ensign Group Reports Third Quarter 2009 Adjusted Earnings of $0.38 per Share 4Health News:The Ensign Group Reports Third Quarter 2009 Adjusted Earnings of $0.38 per Share 5Health News:The Ensign Group Reports Third Quarter 2009 Adjusted Earnings of $0.38 per Share 6Health News:The Ensign Group Reports Third Quarter 2009 Adjusted Earnings of $0.38 per Share 7Health News:The Ensign Group Reports Third Quarter 2009 Adjusted Earnings of $0.38 per Share 8Health News:The Ensign Group Reports Third Quarter 2009 Adjusted Earnings of $0.38 per Share 9Health News:The Ensign Group Reports Third Quarter 2009 Adjusted Earnings of $0.38 per Share 10Health News:The Ensign Group Reports Third Quarter 2009 Adjusted Earnings of $0.38 per Share 11Health News:The Ensign Group Reports Third Quarter 2009 Adjusted Earnings of $0.38 per Share 12
The MPF cup is specifically designed to achieve high primary stability, a critical factor for long term success....
The cementless biomEx cup can be used with both cemented and cementless femoral stems....
Trident Hemispherical Acetabular Shells are a true hemispherical shape designed to achieve press-fit fixation by under-reaming the acetabulum....
For primary and revision cases...
Medicine Products: